<DOC>
	<DOCNO>NCT00028483</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Monoclonal antibody locate tumor cell deliver tumor-killing substance without harm normal cell . Combining chemotherapy monoclonal antibody therapy may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine docetaxel monoclonal antibody therapy treat woman metastatic recurrent breast cancer .</brief_summary>
	<brief_title>Monoclonal Antibody Therapy Docetaxel Treating Women With Metastatic Recurrent Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine toxicity safety profile doxorubicin-monoclonal antibody BR96 immunoconjugate ( SGN-15 ) docetaxel woman metastatic recurrent breast cancer . - Determine clinical response rate duration response patient treat regimen . OUTLINE : Patients receive doxorubicin-monoclonal antibody BR96 immunoconjugate ( SGN-15 ) IV 2 hour docetaxel IV 30 minute day 1 week 1-6 . Treatment repeat every 8 week 6 course absence disease progression unacceptable toxicity . Patients follow 4 week . PROJECTED ACCRUAL : A maximum 45 patient accrue study within 18-24 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunoconjugates</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic recurrent breast carcinoma Unresectable disease Previously treat 2 chemotherapy regimen metastatic disease OR Recurrent within 6 month adjuvant chemotherapy Must one following : Measurable disease Positive bone scan elevation serum tumor marker adenocarcinoma Serum level must increase 2 consecutive measurement exceed least 2 time upper limit normal Lewisy antigen expression document immunohistochemistry No brain metastasis uncontrolled require active treatment ( include steroid ) Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Sex : Female Menopausal status : Not specify Performance status : ECOG 02 Life expectancy : At least 3 month Hematopoietic : Hemoglobin least 10 g/dL Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 No bleed diathesis Hepatic : Bilirubin great 1.5 mg/dL SGOT great 2.5 time normal Alkaline phosphatase great 2.5 time normal ( unless document bony metastasis present ) Amylase/lipase le 1.5 time normal Hepatitis B C negative No hepatic failure Renal : Creatinine great 1.5 time upper limit normal No renal failure Cardiovascular : LVEF great 50 % echocardiogram MUGA scan No congestive heart failure Other : HIV negative No antibody present detects monoclonal antibody BR96 serum No peripheral neuropathy grade 2 great No dementia alter mental status No serious underlie medical condition would preclude study participation No prior allergic reaction recombinant human murine proteins No uncontrolled peptic ulcer disease No active viral , bacterial , systemic fungal infection No primary malignancy except nonmelanoma skin cancer carcinoma situ cervix No serious nonmalignant disease Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : At least 8 week since prior therapeutic diagnostic murine/humanized/human chimeric antibody Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy ( 6 week nitrosoureas , carboplatin , mitomycin , anthracyclines ) No prior cumulative anthracycline 300 mg/m2 No concurrent antineoplastic agent Endocrine therapy : See Disease Characteristics At least 4 week since prior hormonal therapy No concurrent hormonal therapy except estrogen replacement Radiotherapy : At least 4 week since prior radiotherapy Surgery : See Disease Characteristics Other : No concurrent experimental agent No concurrent immunosuppressive medication</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>